Chinese General Practice ›› 2024, Vol. 27 ›› Issue (09): 1054-1061.DOI: 10.12114/j.issn.1007-9572.2023.0571
Special Issue: 内分泌代谢性疾病最新文章合集; 泌尿系统疾病最新文章合集
• Original Research • Previous Articles Next Articles
Received:
2023-08-21
Revised:
2023-11-06
Published:
2024-03-20
Online:
2023-12-19
Contact:
SEN Gan
通讯作者:
森干
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0571
组别 | 例数 | 性别[例(%)] | 年龄( | BMI ( | 糖尿病病程[M(QR),年] | WBC ( | TC ( | TG [M(QR),mmol/L] | HDL-C ( | LDL-C ( | Scr [M(QR),μmol/L] | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||||
非DN组 | 5 329 | 3 328(62.5) | 2 001(37.5) | 56.9±12.1 | 26.0±3.7 | 6(10) | 7.098±2.645 | 4.24±1.18 | 1.64(1.37) | 1.10±0.36 | 2.70±0.87 | 65.32(23.55) |
DN组 | 481 | 343(71.3) | 138(28.7) | 60.5±11.6 | 26.4±4.0 | 14(12) | 7.480±2.736 | 4.55±1.66 | 1.78(1.63) | 1.07±0.32 | 2.88±1.13 | 85.00(48.46) |
检验统计量值 | 14.885a | 39.172 | 4.849 | -15.815b | 9.165 | 27.451 | -3.375b | 2.534 | 17.213 | -16.934b | ||
P值 | <0.001 | <0.001 | 0.028 | <0.001 | 0.002 | <0.001 | <0.001 | 0.111 | <0.001 | <0.001 | ||
组别 | 高血压[例(%)] | SBP ( | DBP ( | HbA1c ( | ApoA1 ( | ApoB ( | Up [M(QR),mmol/L] | Upn[例(%)] | ||||
- | + | ++ | +++ | |||||||||
非DN组 | 2 952(55.4) | 127±16 | 77±10 | 8.72±2.12 | 1.166±0.254 | 0.920±0.280 | 42.8(55.6) | 4 964(93.2) | 168(3.2) | 108(2.0) | 91(1.6) | |
DN组 | 400(83.2) | 136±20 | 78±11 | 9.01±2.11 | 1.160±0.250 | 0.965±0.358 | 403.2(2 079.6) | 188(39.1) | 61(12.7) | 81(16.8) | 151(31.4) | |
检验统计量值 | 176.582a | 134.245 | 9.336 | 8.116 | 0.215 | 11.006 | 1 697.178b | 1 504.049a | ||||
P值 | <0.001 | <0.001 | 0.002 | 0.004 | 0.643 | 0.001 | <0.001 | <0.001 |
Table 1 Comparison of general information between the non-DN group and DN group
组别 | 例数 | 性别[例(%)] | 年龄( | BMI ( | 糖尿病病程[M(QR),年] | WBC ( | TC ( | TG [M(QR),mmol/L] | HDL-C ( | LDL-C ( | Scr [M(QR),μmol/L] | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||||
非DN组 | 5 329 | 3 328(62.5) | 2 001(37.5) | 56.9±12.1 | 26.0±3.7 | 6(10) | 7.098±2.645 | 4.24±1.18 | 1.64(1.37) | 1.10±0.36 | 2.70±0.87 | 65.32(23.55) |
DN组 | 481 | 343(71.3) | 138(28.7) | 60.5±11.6 | 26.4±4.0 | 14(12) | 7.480±2.736 | 4.55±1.66 | 1.78(1.63) | 1.07±0.32 | 2.88±1.13 | 85.00(48.46) |
检验统计量值 | 14.885a | 39.172 | 4.849 | -15.815b | 9.165 | 27.451 | -3.375b | 2.534 | 17.213 | -16.934b | ||
P值 | <0.001 | <0.001 | 0.028 | <0.001 | 0.002 | <0.001 | <0.001 | 0.111 | <0.001 | <0.001 | ||
组别 | 高血压[例(%)] | SBP ( | DBP ( | HbA1c ( | ApoA1 ( | ApoB ( | Up [M(QR),mmol/L] | Upn[例(%)] | ||||
- | + | ++ | +++ | |||||||||
非DN组 | 2 952(55.4) | 127±16 | 77±10 | 8.72±2.12 | 1.166±0.254 | 0.920±0.280 | 42.8(55.6) | 4 964(93.2) | 168(3.2) | 108(2.0) | 91(1.6) | |
DN组 | 400(83.2) | 136±20 | 78±11 | 9.01±2.11 | 1.160±0.250 | 0.965±0.358 | 403.2(2 079.6) | 188(39.1) | 61(12.7) | 81(16.8) | 151(31.4) | |
检验统计量值 | 176.582a | 134.245 | 9.336 | 8.116 | 0.215 | 11.006 | 1 697.178b | 1 504.049a | ||||
P值 | <0.001 | <0.001 | 0.002 | 0.004 | 0.643 | 0.001 | <0.001 | <0.001 |
变量 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
糖尿病病程 | 0.068 | 0.011 | 6.095 | <0.001 | 1.070 | 1.047~1.094 |
TC | 0.231 | 0.066 | 3.483 | <0.001 | 1.260 | 1.109~1.439 |
Scr | 0.008 | 0.002 | 3.378 | 0.001 | 1.008 | 1.004~1.013 |
高血压(以否为参照) | 0.776 | 0.185 | 4.192 | <0.001 | 2.174 | 1.517~3.137 |
Upn(以-为参照) | ||||||
+ | 1.839 | 0.292 | 6.297 | <0.001 | 6.288 | 3.607~11.390 |
++ | 2.260 | 0.318 | 7.113 | <0.001 | 9.587 | 5.290~18.533 |
+++ | 3.095 | 0.387 | 7.993 | <0.001 | 22.098 | 10.960~50.992 |
Table 2 Multivariate Logistic regression analysis used to analyze the influencing factors of DN in T2DM patients
变量 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
糖尿病病程 | 0.068 | 0.011 | 6.095 | <0.001 | 1.070 | 1.047~1.094 |
TC | 0.231 | 0.066 | 3.483 | <0.001 | 1.260 | 1.109~1.439 |
Scr | 0.008 | 0.002 | 3.378 | 0.001 | 1.008 | 1.004~1.013 |
高血压(以否为参照) | 0.776 | 0.185 | 4.192 | <0.001 | 2.174 | 1.517~3.137 |
Upn(以-为参照) | ||||||
+ | 1.839 | 0.292 | 6.297 | <0.001 | 6.288 | 3.607~11.390 |
++ | 2.260 | 0.318 | 7.113 | <0.001 | 9.587 | 5.290~18.533 |
+++ | 3.095 | 0.387 | 7.993 | <0.001 | 22.098 | 10.960~50.992 |
[1] |
|
[2] |
|
[3] |
刘小株. 基于机器学习算法的2型糖尿病肾脏疾病的辅助诊断研究[D]. 重庆:重庆医科大学,2021.
|
[4] |
|
[5] | |
[6] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2010年版)[J]. 中国糖尿病杂志,2012,20(1):81-117.
|
[7] |
施培花,潘莉,费辉辉. 不同孕期多囊卵巢综合征患者发生妊娠期高血压疾病风险预测模型构建与验证[J]. 中国妇幼保健,2022,37(14):2605-2609. DOI:10.19829/j.zgfybj.issn.1001-4411.2022.14.023.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] | |
[13] |
黄晓,邵旻婧,王嘉琪,等. 预测年轻乳腺癌患者生存率列线图的建立和验证[J]. 现代肿瘤医学,2022,30(17):3120-3126. DOI:10.3969/j.issn.1672-4992.2022.17.011.
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
侯新月,胡松,费春晓,等. 预测糖尿病患者并发糖尿病肾病风险的列线图模型的建立[J]. 临床肾脏病杂志,2020,20(3):207-212. DOI:10.3969/j.issn.1671-2390.2020.03.007.
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
田蓉,傅桂芬,李丽蓉,等. 老年T2DM合并高血压患者发生糖尿病肾病的影响因素[J]. 心血管康复医学杂志,2023,32(1):4-8. DOI:10.3969/j.issn.1008-0074.2023.01.02.
|
[24] |
白倩,陈琰,石雪,等. 2型糖尿病合并微血管病变的临床特征及危险因素[J]. 临床与病理杂志,2018,38(7):1493-1498. DOI:10.3978/j.issn.2095-6959.2018.07.020.
|
[25] |
彭方书,赵晓溪,吕燕,等. 2型糖尿病合并高血压患者动态血糖与昼夜动态血压波动的关系[J]. 中国医药导报,2020,17(26):113-116.
|
[26] |
缪春霞,郭琳娜,钟晓连. 尿蛋白和尿微量白蛋白在糖尿病肾病检验中的效果分析[J]. 糖尿病新世界,2022,25(24):65-67,71. DOI:10.16658/j.cnki.1672-4062.2022.24.065.
|
[27] |
卢作维,刘涛,刘向阳,等. 2型糖尿病患者发生微量白蛋白尿预测模型的建立与验证研究[J]. 中国全科医学,2021,24(36):4653-4660. DOI:10.12114/j.issn.1007-9572.2021.02.057.
|
[28] |
徐刚. 尿蛋白与尿肌酐的比值、β2微球蛋白及视黄醇结合蛋白联合检测对糖尿病肾病的早期诊断价值[J]. 实用临床医药杂志,2020,24(21):86-89. DOI:10.7619/jcmp.202021025.
|
[29] |
石安平,冯丽珍,陶敏,等. 糖尿病肾病患者糖化血红蛋白、胱抑素C及血脂水平调查研究[J]. 武警后勤学院学报(医学版),2013,22(5):400-402. DOI:10.3969/j.issn.2095-3720.2013.05.018.
|
[30] |
周玉萍,迟海燕,王永笛. 糖尿病肾病不同分期血清同型半胱氨酸、三酰甘油、总胆固醇水平的变化[J]. 疑难病杂志,2014,13(11):1137-1139. DOI:10.3969/j.issn.1671-6450.2014.11.011.
|
[31] |
|
[32] |
崔颖,贺建勋,林红军. 血尿酸、血肌酐水平对糖尿病肾病患者预后判断的价值[J]. 中国社区医师,2021,37(34):95-96.
|
[33] |
章晓炎,盛虹,谢静远,等. 高尿酸血症与老年慢性肾脏病患者肾功能的相关性研究[J]. 内科理论与实践,2020,15(3):161-166. DOI:10.16138/j.1673-6087.2020.03.006.
|
[1] | WANG Xueting, JIANG Yi. Disease Burden of Chronic Obstructive Pulmonary Disease in the BRICS Countries from 1990 to 2019 [J]. Chinese General Practice, 2024, 27(09): 1118-1125. |
[2] | WANG Kai, XU Baichao, WANG Zhaoxin, SU Jianjiao. Effects of Combined Motion Intervention on Body Composition, Cardiovascular Risk Factors and Cardiopulmonary Fitness of Obese Female Adolescents [J]. Chinese General Practice, 2024, 27(09): 1109-1117. |
[3] | ZOU Qiong, WU Xi, ZHANG Yang, WAN Yi, CHEN Changsheng. Prediction of Type 2 Diabetic Nephropathy Based on BP Neural Network Optimized by Sparrow Search Algorithm [J]. Chinese General Practice, 2024, 27(08): 961-970. |
[4] | YUAN Yuan, ZHANG Yarong, LI Zhengang, ZHANG Li. Risk Factors of Prone Position Ventilation-related Facial Pressure Injuries and the Selection of Best Modeling Method [J]. Chinese General Practice, 2024, 27(08): 948-954. |
[5] | WU Shuqin, WANG Yuanhan, ZHENG Kaiyuan, HAN Hongjuan, KANG Jinxiu, YU Hongmei. Prognosis and Influencing Factors of Patients with Malignant Melanoma [J]. Chinese General Practice, 2024, 27(08): 942-947. |
[6] | CHEN Qianqian, RUI Fajuan, NI Wenjing, LI Jie. Research Progress in Epidemiology and Risk Factors of Primary Liver Cancer [J]. Chinese General Practice, 2024, 27(06): 637-642. |
[7] | DONG Wendi, YANG Jiani, ZHU Jie, QUAN Yujie, ZHANG Jinjing, LIU Yan, ZHANG Hairong. Study of Factors Associated with Concomitant Gastrointestinal Bleeding in Patients with Portal Vein Thrombosis in Liver Cirrhosis [J]. Chinese General Practice, 2024, 27(05): 552-556. |
[8] | FAN Caixia, LI Jiao, WEI Yanjin, GUO Dequn, LIU Cunfei, LI Zhengrong, QIU Shi. Influencing Factors of Overanticoagulation at Initial Stage of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation [J]. Chinese General Practice, 2024, 27(03): 308-314. |
[9] | YANG Mukun, JIA Xiaoxiang, REN Zhenghong, GU Bei, BAI Wenpei. Menopause or Chronologic Aging? A Prospective Cohort Study on Risk Factors for Coronary Heart Disease in Middle-aged Women [J]. Chinese General Practice, 2024, 27(03): 280-285. |
[10] | DENG Yuxuan, HUANG Xuejun, JIANG Yanxia. Recent Advances of Metformin in Treatment of Diabetic Nephropathy [J]. Chinese General Practice, 2024, 27(03): 262-267. |
[11] | YANG Ji, ZHANG Yao, MA Teng, TIAN Xintong, ZHAO Yingqiang. Epidemic Status, Disease Burden and Prediction of Cardiovascular Diseases in China, 1990-2019 [J]. Chinese General Practice, 2024, 27(02): 233-244. |
[12] | TANG Can, LI Xiangyang, LI Jing, QIN Haoran, ZHU Hong. The Value of Nomogram Established by Serological Indicators and Tumor Diameter to Predict the Risk of Microvascular Invasion in Hepatocellular Carcinoma [J]. Chinese General Practice, 2023, 26(36): 4514-4520. |
[13] | ZHANG Aili, HOU Qiqi, HAN Quanle, ZHANG Boheng, ZHANG Jiawei, CAO Hongxia, ZHANG Chao, CHEN Shuohua, WU Shouling, LI Kangbo. Correlation between Atrial Fibrillation and the Risk of New-onset Chronic Kidney Disease in Northern Chinese Population [J]. Chinese General Practice, 2023, 26(36): 4521-4526. |
[14] | CHENG Hao, ZHOU Jinchi, LIU Xi, KANG Lin, FAN Ahui, DOU Weijia, LIU Zhenxiong. Risk Factors Analysis and Risk Prediction Model Establishment for Rebleeding Events within 3 Years after Endoscopic Treatment of Gastroesophageal Varices in Liver Cirrhosis Patients [J]. Chinese General Practice, 2023, 26(35): 4446-4452. |
[15] | LU Yihan, WANG Jiwen, SUN Yue, FENG Runrun, HAN Yufei, SONG Zhenzhen, SUN Ying, DAI Huihua, CHEN Xing. Risk Factors and Maternal and Neonatal Outcomes of Pregnant Women with Total Labor over 24 Hours [J]. Chinese General Practice, 2023, 26(35): 4459-4463. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||